Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pola-ZRCHP in Previously Untreated DLBCL
NCT07608978Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of polatuzumab vedotin, zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Provincial People's Hospital. Started Jun 2026; status: recruiting.
02
Drugs
polatuzumab vedotinzanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07608978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07608978.